Document is current
Any future updates will be listed below
-
Authors
Masi, Mirco https://orcid.org/0000-0003-0919-5206
Poppi, Laura
Previtali, Viola
Nelson, Shannon R.
Wynne, Kieran
Varignani, Giulia
Falchi, Federico https://orcid.org/0000-0001-7385-649X
Veronesi, Marina
Albanesi, Ennio
Tedesco, Daniele https://orcid.org/0000-0003-2585-7791
De Franco, Francesca
Ciamarone, Andrea
Myers, Samuel H.
Ortega, Jose Antonio
Bagnolini, Greta
Ferrandi, Giovanni https://orcid.org/0009-0004-1656-2961
Farabegoli, Fulvia
Tirelli, Nicola
Di Stefano, Giuseppina https://orcid.org/0000-0003-0375-0176
Oliviero, Giorgio https://orcid.org/0000-0002-1257-359X
Walsh, Naomi https://orcid.org/0000-0002-2178-3564
Roberti, Marinella
Girotto, Stefania https://orcid.org/0000-0002-0339-6675
Cavalli, Andrea
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (Post-doc Fellowship 2023, id 28174, IG project 2018, id 21386)
MS analysis here performed was supported by The Comprehensive Molecular Analytical Platform (CMAP) under The SFI Research Infrastructure Programme
Ministero dell'Istruzione, dell'Università e della Ricerca (PRIN2022, project number 20227S3BM7)
- License Information
-
More Information
Article History
Received: 14 October 2024
Revised: 16 January 2025
Accepted: 28 February 2025
First Online: 16 March 2025
Competing interests
: VP, FDF, JAO, GB, RP, GDS, MR and ACa are co-inventors on a patent application (WO 2021/116999 A1, ‘Compounds and compositions for the treatment of tumors’, PCT/IB2020/061825) protecting the compound(s) disclosed in this article.
: All the methods were performed in accordance with the relevant guidelines and regulations. The in vitro experiments (recombinant proteins and cells) performed in this work did not use material that requires ethical approval and no experiments were conducted on animals or human patients’ samples.
: Consent for publication of the article has been obtained from all participants.
